Trial Profile
A 24-month Multi-center, Open-label, Randomized, Controlled Study to Evaluate the Evolution of Renal Function in Maintenance Liver Transplant Recipients Receiving Either RAD001 (Everolimus) Plus Reduced TAC or RAD001 (Everolimus) Plus Mycophenolate Mofetil (MMF)
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase III
Latest Information Update: 01 Aug 2018
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Ciclosporin; Mycophenolate mofetil; Mycophenolate sodium; Tacrolimus
- Indications Liver transplant rejection
- Focus Therapeutic Use
- Acronyms Prometheus
- Sponsors Novartis Pharmaceuticals
- 01 Oct 2015 New trial record